What Peptide Therapy Is and Isn't: A Physician's Honest Take
What Peptide Therapy Is and Isn’t: A Physician’s Honest Take
Peptide therapy occupies a peculiar position in modern medicine. It is simultaneously one of the most promising and most overhyped areas in longevity-oriented practice. Depending on who you ask, peptides are either the next frontier of medical science or the latest vehicle for unfounded claims and expensive placebo.
The truth, as usual, resides between the extremes. Some peptides have robust clinical evidence. Others have compelling preclinical data that has not yet been validated in humans. Others have little evidence at all and are marketed on anecdote and enthusiasm.
A physician prescribing peptides should be able to tell you exactly where on this spectrum each recommendation falls.
What Peptides Are
Peptides are short chains of amino acids, typically between 2 and 50 amino acids in length. They are distinguished from full proteins, which are longer chains, and from individual amino acids. The body produces thousands of endogenous peptides that function as hormones, neurotransmitters, growth factors, and signalling molecules.
Pharmaceutical peptide therapy uses synthetic or recombinant versions of these molecules, or novel peptide sequences, to produce specific biological effects. The administration route varies by peptide: subcutaneous injection, oral administration, nasal spray, or topical application.
Where the Evidence Is Strong
GLP-1 Receptor Agonists
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are modified peptides that mimic the incretin hormone GLP-1. They are among the most rigorously studied pharmaceuticals in modern medicine.
The evidence base includes multiple large randomized controlled trials demonstrating significant weight loss (15 to 20+ percent of body weight), improvement in HbA1c and insulin sensitivity, reduction in cardiovascular events (the SELECT trial demonstrated a 20 percent reduction in major adverse cardiovascular events with semaglutide in non-diabetic obese adults), and improvement in metabolic syndrome criteria. This matters because body composition drives disease risk. The relationship between visceral adiposity and metabolic health is linear and dose-responsive. A person with excess visceral fat is at elevated risk for insulin resistance, cardiovascular disease, and cognitive decline. GLP-1 agonists work partly by reducing total fat mass but also by shifting body composition—reducing visceral fat preferentially while preserving lean mass. This is not just weight loss. It is metabolic restoration.
GLP-1 receptor agonists are Health Canada approved, widely prescribed, and represent a genuine advance in the treatment of obesity and metabolic disease. Their role in longevity medicine extends beyond weight loss to cardiovascular risk reduction, improvement in hepatic steatosis, and systemic inflammation reduction.
These are not speculative. They are evidence-based pharmaceutical interventions with a growing body of long-term safety and efficacy data.
Insulin and Insulin Analogues
Insulin itself is a peptide. Therapeutic insulin and its analogues have been used for over a century and represent the most established peptide therapy in medicine.
Growth Hormone (in Specific Indications)
Recombinant human growth hormone (rhGH) is approved for specific diagnoses: adult growth hormone deficiency (confirmed by stimulation testing), Turner syndrome, and several other defined conditions. In these populations, the evidence for efficacy and safety is established.
The off-label use of growth hormone for general longevity or performance enhancement in adults without documented deficiency is a different proposition. The evidence does not support routine growth hormone use for healthy aging adults. Potential risks include insulin resistance, fluid retention, joint pain, and theoretical concerns about cancer promotion. The risk-benefit ratio in healthy adults does not clearly favour treatment.
Where the Evidence Is Promising but Incomplete
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. Preclinical studies (primarily in rodent models) have demonstrated accelerated healing of tendons, ligaments, muscles, intestinal tissue, and bone. The proposed mechanisms include promotion of angiogenesis, modulation of the nitric oxide system, and growth factor upregulation.
BPC-157 is widely used in longevity and sports medicine clinics. Patient reports of improved healing from musculoskeletal injuries are common. However, human clinical trial data is sparse. No large randomized controlled trials have been published. The dosing, duration, and safety profile in humans remain incompletely defined.
BPC-157 is a reasonable area of clinical interest, but patients should understand that the evidence supporting its use is preclinical and anecdotal, not clinical-grade.
Thymosin Beta-4 (TB-500)
TB-500 is a synthetic fragment of thymosin beta-4, a peptide involved in tissue repair and inflammation modulation. Like BPC-157, the preclinical evidence for tissue healing is encouraging, and clinical reports are favourable. Human trial data is limited.
PT-141 (Bremelanotide)
Bremelanotide is an FDA-approved peptide (marketed as Vyleesi) for the treatment of hypoactive sexual desire disorder in premenopausal women. It acts on melanocortin receptors in the brain to increase sexual desire. The clinical trial data supporting its efficacy is established for this specific indication.
Off-label use in men and in postmenopausal women is common in clinical practice but less well supported by published evidence.
Where the Evidence Is Weak or Absent
Growth Hormone Secretagogues (Ipamorelin, CJC-1295, Sermorelin, Tesamorelin)
These peptides stimulate the pituitary to release endogenous growth hormone. They are widely offered in longevity clinics as an alternative to direct growth hormone administration, with claims about improved body composition, sleep, skin quality, and recovery.
The clinical evidence for most of these compounds in healthy adults is thin. Tesamorelin has FDA approval for the reduction of visceral adipose tissue in HIV-associated lipodystrophy and has the strongest evidence base in this class, but for a specific population and indication.
For the general longevity population, the evidence that growth hormone secretagogues produce clinically meaningful and durable benefits at the doses commonly prescribed is insufficient to make strong recommendations.
Melanotan II
Used for skin tanning and sometimes for sexual dysfunction, melanotan II has no regulatory approval and carries risks including nausea, facial flushing, and potential promotion of melanocytic nevi. The safety profile is inadequately characterized.
How to Evaluate Peptide Offerings
Patients should ask their physician several questions before starting any peptide therapy:
What is the specific clinical evidence for this peptide at this dose for my indication? Is the evidence from human trials or animal models? Is this peptide Health Canada approved or available through a regulated pharmacy? What are the known risks and side effects? How will you monitor my response?
A physician who can cite specific human trials and explain the risk-benefit ratio for your individual situation is practicing medicine. A physician who relies entirely on mechanism-of-action explanations and patient testimonials is selling an idea.
Both categories can coexist in the same practice. A good clinician distinguishes between what is proven and what is plausible, and communicates that distinction to the patient.
How Peptides Fit into the Broader Picture
At Manus Solis, peptide therapy is considered within the context of a comprehensive treatment plan, not as a standalone offering. Hormonal optimization, metabolic correction, exercise prescription, and sleep restoration are addressed first. Peptides are considered when they add value to an already optimized foundation.
The foundations are non-negotiable: body composition assessment and improvement, cardiovascular fitness development, sleep restoration, and hormonal balance. These are the interventions with the strongest evidence for mortality benefit and health span extension. A GLP-1 agonist has value because it works within this context—helping a dysmetabolic patient achieve the body composition target that exercise and diet alone have not achieved. Peptides are adjuncts to the foundation, not replacements for it.
A patient taking a GLP-1 agonist for metabolic health is receiving an evidence-based intervention. A patient using BPC-157 for a tendon injury is receiving a promising but not yet proven intervention. Both can be appropriate, provided the patient understands the distinction and the monitoring is in place.
The honest position is this: some peptides represent genuine medical advances. Others are early-stage and promising. Others are riding a wave of enthusiasm that outpaces the evidence. Knowing which is which is the physician’s responsibility. And every peptide prescription should pass a simple test: does this bring the patient closer to the measurable targets that predict longer, healthier living?
Continue Reading
If you found this useful, these related articles may deepen your understanding:
- Supplements That Matter vs. Placebos
- Data-Driven Medicine: Why We Measure Everything
- Testosterone for Women
Dr. Handsun Xiao is a McGill trained physician (MD, CCFP) practicing functional medicine and bioidentical hormone therapy in Toronto, with virtual consultations available to patients across Ontario. He holds advanced BHRT certification through WorldLink Medical and IFM AFMCP training. Manus Solis offers physician led BHRT consultations with custom compounding through a dedicated Ontario pharmacy partner. To learn more or book a virtual consultation, visit manussolis.ca.
Continue Reading